1. Introduction {#j_med-2019-0048_s_001}
===============

Angiosarcoma (AS) is a rapid growth tumour of endothelial origin, which accounts for less than 2% of soft tissue sarcomas \[[@j_med-2019-0048_ref_001]\]. Most cases happen in older white men with an extremely high mortality rate mainly due to distant metastasis at the time of diagnosis or shortly afterwards. According to the World Health Organization (WHO), mean survival of 7.7 months was met \[[@j_med-2019-0048_ref_002]\].

Endothelial cells are considered the source of AS, but an origin from circulating stem cells recruited from bone marrow or extra-medullary hematopoiesis is argued \[[@j_med-2019-0048_ref_003], [@j_med-2019-0048_ref_004]\]. The skin accounts for approximately one-third of cases, especially in the head and neck region or the extremities \[[@j_med-2019-0048_ref_005]\]. Regardless of the primary organ affected, the five years overall survival rate is estimated to be 10-35%, with metastases found commonly in the lungs, liver, and bone, because of early hematogenous dissemination \[[@j_med-2019-0048_ref_006]\].

The bulk of the related literature describes the origin in a healthy kidney as a site of uncommon primary occurrence, reporting only a case of primary AS associated with a renal angiomyolipoma \[[@j_med-2019-0048_ref_007]\]. Some pathological conditions were listed as predisposing factors, but no direct causal relationship was ever demonstrated \[[@j_med-2019-0048_ref_008], [@j_med-2019-0048_ref_009], [@j_med-2019-0048_ref_010]\], as well as vinyl chloride, thorium dioxide, or radiation exposition \[[@j_med-2019-0048_ref_009]\]. The role of some genes involved in the receptor protein tyrosine kinase pathway was recently described \[[@j_med-2019-0048_ref_011]\].

The radiological diagnosis of this neoplasm is quite challenging because of the various overlapping characteristics with other tumoural subtypes. Thus, pathological examination with immune-histochemical findings remains essential. The surgical approach seems to ensure the more significant advantage in terms of prognosis, with adjuvant radio- and chemotherapy proposed to improve the cancer-specific survival, even if no standard treatment can be still set. However, in advanced renal disease, the role of surgery is still debated, mainly due to the significant morbidity and the development of effective adjuvant systemic therapies.

This study aimed to describe the first case of AS with extensive necrosis occurring in our Institute, interesting the left kidney. The follow-up was of 15 months until the patient died of the disease. In an attempt to identify prognostic factors and optimal treatment strategy, we also performed a comprehensive literature review, thus improving the knowledge about the aggressive behaviour of this tumour.

2. Material and methods {#j_med-2019-0048_s_002}
=======================

To provide helpful information to treat our case, we searched the published papers with the terms of 'primary angiosarcoma of the kidney' and 'primary renal angiosarcoma' in PubMed, Scopus, Google Scholar, and Embase databases, without language limitation. All articles and case reports of primary AS of the kidney until December 2018 were included. We obtained clinical and pathological data, including maximum tumour dimension measured in centimetres, laterality, and immune-histochemical expression of the tumour cells.

Informed consent has been obtained from patient included in this study.

Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration.

3. Case report {#j_med-2019-0048_s_003}
==============

A 56-years-old male patient presented to the "Santa Maria della Misericordia" Hospital (Perugia, Italy) with left flank pain. An abdominal ultrasound scan detected a mass in the middle third of the left kidney measuring 8 x 10 cm, toward the lower pole, relatively round shaped. A whole-body Computed Tomography (CT) scan confirmed the presence of 11 cm lower pole mass in the left kidney. It appeared poorly vascularized by the appearance of large central collapsed area with signs of the infiltration of perirenal fat and perirenal band and various small lymph nodes under centimetres at the level of the mesenteric fan ([Figure 1](#j_med-2019-0048_fig_001){ref-type="fig"}). The rapid peripheral enhance-wash-out of the contrast agent in the early arterial phase suggested a

![Preoperative computed tomography (ct) scan (a: axial reconstruction; b: coronal reconstruction) showing a mass with a poor vascularization and a collapsed area in the lower pole of the left kidney.](med-14-443-g001){#j_med-2019-0048_fig_001}

Renal Cell Carcinoma (RCC). No signs of the infiltration of the arterial-venous vascular peduncle or distant metastases were detected, confirmed after that by a bone scan.

The patient presented a single preoperative episode of macroscopic hematuria after diagnostic imaging. One day before surgery, we performed a left renal artery catheter embolisation using a Haemostatic Absorbable Gelatin Sponge (Spongostan, Ethicon™, Somerville, NJ, USA) and polyvinyl alcohol to decrease intraoperative bleeding risk. Then the patient underwent open radical nephrectomy with hilar and para-aortic lymph node dissection made by an expert urologist surgeon (EM) \[[@j_med-2019-0048_ref_012], [@j_med-2019-0048_ref_013], [@j_med-2019-0048_ref_014]\]. We removed the perirenal fat tissue, the ipsilateral adrenal gland, a 25 mm tract of the ureter, and the middle portion of the ileo-psoas muscle.

According to our review, radical nephrectomy is the most effective treatment for primary AS ([Table 1](#j_med-2019-0048_tab_001){ref-type="table"}); surgery was not listed as primary treatment in only 2 cases \[[@j_med-2019-0048_ref_015], [@j_med-2019-0048_ref_016]\].

###### 

Literature review of primary kidney angiosarcoma

  Author                                                   Age (yy)   Sex   Side   Clinical presentation                             Size (cm)   Mets   Sites (initial and subsequent mets)             Treatment                     Follow-up (months)   Outcome
  -------------------------------------------------------- ---------- ----- ------ ------------------------------------------------- ----------- ------ ----------------------------------------------- ----------------------------- -------------------- ------------
  Qayyum et al.\[[@j_med-2019-0048_ref_014]\]              86         M     R      wl, fatigue, dizziness                            12.3        Yes    Liver, lungs                                    Palliative (patient's wish)   NA                   NA
  Zhang et al.\[[@j_med-2019-0048_ref_039]\]               52         M     L      fp, left leg pain                                 8           Yes    Liver, bone                                     Nephr                         NA                   NA
  Liu et al.\[[@j_med-2019-0048_ref_038]\]                 75         M     R      hematuria                                         4           No     No                                              Nephr, RT                     6                    NED
  Brown et al.\[[@j_med-2019-0048_ref_043]\]               68         M     R      NA                                                24          Yes    Liver                                           NA                            6                    DOD
  Brown et al.\[[@j_med-2019-0048_ref_043]\]               64         M     L      NA                                                30          No     No                                              NA                            11                   DOD
  Brown et al.\[[@j_med-2019-0048_ref_043]\]               71         M     L      NA                                                10          Yes    Peritoneal and periaortic LN                    NA                            1                    DOD
  Brown et al.\[[@j_med-2019-0048_ref_043]\]               72         M     L      NA                                                NA          No     No                                              NA                            NA                   NA
  Brown et al.\[[@j_med-2019-0048_ref_043]\]               29         F     L      NA                                                3.7         NA     NA                                              NA                            1                    DOD
  Brown et al.\[[@j_med-2019-0048_ref_043]\]               62         M     NA     NA                                                NA          NA     NA                                              Nephr                         NA                   NA
  Brown et al.\[[@j_med-2019-0048_ref_043]\]               67         M     R      NA                                                NA          NA     NA                                              Nephr                         NA                   NA
  Brown et al.\[[@j_med-2019-0048_ref_043]\]               95         M     R      NA                                                15.5        NA     NA                                              Nephr                         2                    DFUD
  Cason et al.\[[@j_med-2019-0048_ref_018]\]               46         M     L      fp, wl                                            13          No     Bone, liver, abdominal soft tissue              Nephr, chemotherapy, RT       10                   DOD
  Allred et al.\[[@j_med-2019-0048_ref_044]\]              67         M     R      fp, hematuria                                     13          Yes    Lungs, liver                                    Nephr, chemotherapy           3                    DOD
  Peters et al.\[[@j_med-2019-0048_ref_045]\]              74         M     L      wl                                                19          Yes    Lungs, liver, abdominal wall, head              Nephr                         2                    DOD
  Prince et al.\[17\]                                      51         M     L      fp, hematuria                                     10          No     No                                              Nephr, RT                     NA                   A&W
  Sabharwal et al.\[[@j_med-2019-0048_ref_040]\]           67         M     L      loin pain, wl, loss of appetite                   13          Yes    Spleen                                          Nephr, chemotherapy           1                    NA
  Chaabouni et al.\[[@j_med-2019-0048_ref_046]\]           59         M     R      fp, hematuria                                     6.5         No     No                                              Nephr                         1                    DOD
  López Cubillana et al.\[[@j_med-2019-0048_ref_047]\]     72         M     R      hematuria                                         13          No     Bone and lung                                   Nephr, chemotherapy           5                    DOD
  Singh et al.\[[@j_med-2019-0048_ref_033]\]               83         M     L      hematuria                                         13          No     No                                              NA                            NA                   NA
  Askari et al.\[[@j_med-2019-0048_ref_048]\]              24         M     R      hematuria, ureteric obstruction                   9           No     No                                              Nephr                         4                    DOD
  Douard et al.\[[@j_med-2019-0048_ref_049]\]              60         M     R      NA                                                NA          Yes    Bone, lung                                      Nephr                         3                    DOD
  Terris et al.\[[@j_med-2019-0048_ref_036]\]              47         M     L      fp                                                19          Yes    Diaphragm, renal artery, liver and bone         Nephr, RT                     10                   DOD
  Zenico et al.\[[@j_med-2019-0048_ref_050]\]              56         M     L      incidental finding                                20          No     No                                              Nephr                         4                    DOD
  Desai et al.\[[@j_med-2019-0048_ref_051]\]               54         M     L      fp, hematuria                                     21          No     Bone                                            Nephr, chemotherapy           4                    DOD
  Johnson et al.\[[@j_med-2019-0048_ref_015]\]             50         M     L      fp, hemoptysis                                    9           Yes    Liver, lung                                     Rapid deterioration           NA                   DOD
  Kern et al.\[[@j_med-2019-0048_ref_052]\]                69         M     L      fp, wl, hematuria                                 26          Yes    Lung                                            Nephr                         1.5                  DOD
  Kern et al.\[[@j_med-2019-0048_ref_052]\]                52         M     L      hematuria                                         8           Yes    Lung                                            Nephr                         3                    DOD
  Fukunaga et al.\[[@j_med-2019-0048_ref_032]\]            61         M     L      incidental finding                                8           No     Liver, bone and retroperitoneum                 Nephr                         13                   DOD
  Adjiman et al.\[[@j_med-2019-0048_ref_053]\]             36         M     R      hemoptysis, fp, fever                             10.5        Yes    Chest wall, skin                                Nephr                         NA                   DOD
  Papadimitriou et al.\[[@j_med-2019-0048_ref_009]\]       68         M     L      fp, dysuria, hematuria                            10          No     No                                              Nephr                         NA                   A&W
  Tsuda et al.\[[@j_med-2019-0048_ref_054]\]               77         M     L      hematuria, renal failure                          10          No     Retroperitoneum, liver                          Nephr                         21                   DOD
  Leggio et al.\[[@j_med-2019-0048_ref_034]\]              60         M     L      post-trauma abd pain                              12          No     Spleen, peritoneum                              Nephr                         8                    DOD
  Mordkin et al.\[[@j_med-2019-0048_ref_055]\]             75         M     L      fever, wl                                         19          Yes    Spleen, bone, liver, soft tissue, oral cavity   Nephr, chemotherapy, S        NA                   NA
  Akkad et al.\[[@j_med-2019-0048_ref_035]\]               58         M     R      incidental finding                                4.5         No     No                                              Nephr                         30                   NED
  Cerilli et al.\[[@j_med-2019-0048_ref_056]\]             67         M     R      fp, hematuria                                     12.5        Yes    Renal vein                                      Nephr, RT                     6                    DOD
  Aksoy et al.\[[@j_med-2019-0048_ref_057]\]               55         M     L      abd pain, rupture with retroperitoneal hematoma   13          No     No                                              Nephr, S                      3                    DOD
  Hiratsuka et al.\[[@j_med-2019-0048_ref_019]\]           59         F     R      hematuria                                         4.5         No     No                                              Nephr                         29                   NED
  Aydogdu et al.\[[@j_med-2019-0048_ref_058]\]             77         M     L      NA                                                NA          NA     NA                                              Nephr                         NA                   NA
  Martinez- Pineiro et al.\[[@j_med-2019-0048_ref_037]\]   66         M     L      abd pain, anorexia, asthenia                      11.5        No     Bone, liver, lungs                              Nephr                         5                    DOD
  Lee et al.\[[@j_med-2019-0048_ref_028]\]                 63         M     NA     NA                                                NA          NA     NA                                              NA                            NA                   NA
  Berretta et al.\[[@j_med-2019-0048_ref_059]\]            67         M     NA     NA                                                NA          NA     NA                                              Nephr, chemotherapy           NA                   NA
  Souza et al.\[[@j_med-2019-0048_ref_060]\]               75         M     L      wl, fp, hematuria                                 15          No     No                                              Nephr                         NA                   DFUD
  Costero-Barrios et al.\[[@j_med-2019-0048_ref_061]\]     71         M     L      hematuria, fp                                     18          No     Liver and retroperitoneum                       Nephr, chemotherapy, RT       12                   Recurrence
  Grapsa et al.\[[@j_med-2019-0048_ref_062]\]              65         M     R      fever, fatigue, dyspnea                           13.8        Yes    Liver, lung                                     NA                            NA                   NA
  Carnero Lopez et al.\[[@j_med-2019-0048_ref_022]\]       29         F     L      Hemoptysis                                        11          Yes    Lungs                                           Nephr, chemotherapy           5                    DOD
  Sesar et al.\[[@j_med-2019-0048_ref_063]\]               65         M     L      incidental finding                                4.5         NA     NA                                              Nephro-                       NA                   NA
  Pauli et al.\[[@j_med-2019-0048_ref_063]\]               57         M     L      hemoptysis                                        15          Yes    Lungs, bone                                     ureterectomy Nephr, RT        2                    DOD
  Yoshida et al.\[[@j_med-2019-0048_ref_064]\]             78         M     L      fp                                                18          Yes    Liver, bone                                     Nephr, immunotherapy          13                   DOD
  Juan et al.\[[@j_med-2019-0048_ref_065]\]                81         F     NA     hematuria                                         5           Yes    Liver, bone                                     Nephr, chemotherapy, RT       9                    DOD
  Xuan et al.\[[@j_med-2019-0048_ref_066]\]                63         M     L      pain and costal swelling                          10          NA     NA                                              Nephr                         NA                   NA
  Yau et al.\[[@j_med-2019-0048_ref_067]\]                 38         F     R      hematuria, bone pain                              13          Yes    Bone, LN                                        Nephr, chemotherapy, RT       3                    DOD
  Garmendia et al.\[[@j_med-2019-0048_ref_068]\]           51         M     NA     NA                                                NA          NA     NA                                              NA                            NA                   NA
  Nguyen et al.\[[@j_med-2019-0048_ref_069]\]              53         M     L      hematuria, fp                                     7           Yes    Lung                                            Nephr, chemotherapy           18                   DOD
  Limmer et al.\[[@j_med-2019-0048_ref_070]\]              48         M     L      fp                                                10          No     Lung, soft tissue, muscle                       Nephr                         1                    DOD
  Matter et al.\[[@j_med-2019-0048_ref_071]\]              62         M     L      fp, abd mass                                      18          No     Lung                                            Nephr, chemotherapy, RT       18                   DOD
  Sanyal et al.\[[@j_med-2019-0048_ref_072]\]              30         M     NA     NA                                                NA          No     No                                              Nephr, RT                     24                   DOD
  Testa et al.\[[@j_med-2019-0048_ref_073]\]               NA         NA    NA     NA                                                NA          NA     NA                                              NA                            NA                   NA
  Yamamoto et al.\[[@j_med-2019-0048_ref_074]\]            68         M     R      incidental finding                                7           No     No                                              Nephr, RT                     19                   NED
  Rüb et al.\[[@j_med-2019-0048_ref_075]\]                 59         M     L      hematuria, wl                                     18          No     Lungs, liver                                    Nephr, chemotherapy           12                   AWD
  Celebi et al.\[[@j_med-2019-0048_ref_076]\]              57         M     R      fp, hematuria                                     14          No     Lungs, pelvis                                   Nephr, chemotherapy           13                   DOD
  Li et al.\[[@j_med-2019-0048_ref_077]\]                  69         F     L      NA                                                NA          NA     NA                                              NA                            NA                   NA
  Witczak et al.\[[@j_med-2019-0048_ref_078]\]             44         F     NA     hematuria                                         NA          NA     NA                                              Nephr                         NA                   NA
  Cuadra-Urteaga et al.\[79\]                              44         M     R      hematuria                                         7.5         No     No                                              Nephro- ureterectomy          2                    DOD
  Iannaci et al.\[[@j_med-2019-0048_ref_026]\]             56         M     L      lower back pain and hematuria                     4           Yes    Lungs                                           Nephr                         NA                   DOD
  Su\[80\]                                                 53         F     R      right lower abd pain                              8.5         No     Local advanced                                  Nephr, chemotherapy           NA                   DFUD
  Gourley et al.\[[@j_med-2019-0048_ref_010]\]             NA         M     R      acute right fp                                    12.5        No     No                                              Nephr                         NA                   NA
  Guan et al.                                              64         F     L      fp, fatigue, wl                                   18          No     Local advanced                                  Mass excision, chemotherapy   4                    DOD

**Notes**:

**Abbreviations**: Mets, metastases; dx, diagnosis; M, male; F, female; L, left; R, right; NA, not available; abd, abdominal; fp, flank pain; wl, weight loss; LN, lymph node; Nephr, Nephrectomy; NED, no evidence of disease; DFUD, died from unrelated disease; AWD, alive with disease; DOD, died of disease; RT, radiotherapy; S, splenectomy; A&W, alive and well.

4. Results {#j_med-2019-0048_s_004}
==========

Estimated intraoperative blood loss was 200 mL and operative time was 100 minutes. The hospital stay was eight days long. Seven days after surgery, serum creatinine and eGFR were 0.98 mg/dL and 81 mL/minute, respectively; after three months, these parameters were the same. No postoperative complications occurred. The surgical specimen consisted of the entire left kidney, weighing 1,080 g and measuring 16 x 11.5 x 7 cm with a portion of the striated muscular belly of ileo-psoas, measuring 3.6 x 2.5 cm. The visible appearance of the solid tumour, located in the lower middle third of the kidney, was a cavitated hemorrhagic necrotising mass of about 14 x 9 cm ([Figure 2](#j_med-2019-0048_fig_002){ref-type="fig"}). Specimens were fixed in 10% formalin, embedded in paraffin wax, sectioned at four μm, and stained with hematoxylin and eosin. Histopathological examination showed vasoformative areas with ramifying channels lined by atypical endothelial cells together with more solid areas lacking vasoformative and composed by high-grade spindle-shaped cells with large hyperchromatic nuclei and prominent nucleoli ([Figure 3a)](#j_med-2019-0048_fig_003){ref-type="fig"}. The psoas muscle tissue, surgical margins, ureter, renal artery and vein, and left para-aortic lymph nodes did not appear infiltrated by the tumour. The immune-histochemical study showed strongly and diffusely positive staining for CD31 ([Figure 3b)](#j_med-2019-0048_fig_003){ref-type="fig"}, CD34, Fli-1, and remained harmful for pan-cytokeratin, MelanA, HMB45, PGM1, PAX8, GATA3, CD10, racemase, p63, smooth muscle actin, desmin, HHV8; Ki-67/ Mib 1:50%. These findings indicated that the tumour was an AS of the kidney. Ipsilateral adrenal adenoma was also detected.

![Operative specimen demonstrating.](med-14-443-g002){#j_med-2019-0048_fig_002}

![Angiosarcoma (as) of the kidney. (A) clusters of atypical spindle-shaped cells forming irregular vascular channels and rudimentary lumen formation (haematoxylin-eosin, 200x); (b) immunostain for cd31 shows intense staining of most as cells (200x).](med-14-443-g003){#j_med-2019-0048_fig_003}

After 45 days from the surgical procedure, the patient developed hemoptysis. A total body CT scan was then performed with the evidence of a nodular mass of about 3 cm in the left kidney lodge ([Fig. 4](#j_med-2019-0048_fig_004){ref-type="fig"}) and at the level of the left parietal-colic ligament, both showing contrast enhancement after administration of contrast medium. Furthermore, it showed several nodular opacities of the lungs with ground glass opacity ([Fig. 5](#j_med-2019-0048_fig_005){ref-type="fig"}), and multiples hypodense liver lesions ([Fig. 6](#j_med-2019-0048_fig_006){ref-type="fig"}), suggestive of distant metastases. Therefore, the patient underwent bronchoscopy with bioptic samples. The histological report was negative for neoplastic proliferation. In some macrophages, there was the presence of hemosiderin.

![Axial (a) and coronal (b) reconstruction on ct scan showing a local recurrence of tumoral tissue (red arrow) in the left kidney lodge, alongside the parieto-colic ligament.](med-14-443-g004){#j_med-2019-0048_fig_004}

![CORONAL CT SCAN showing several nodular opacities of the lungs with ground glass opacity and tree-in-bud signs](med-14-443-g005){#j_med-2019-0048_fig_005}

![AXIAL (A) and CORONAL (B) RECONSTRUCTION on CT SCAN showing multiples hypodense liver lesions. The arrow point the biggest one of almost 10 mm of diameter.](med-14-443-g006){#j_med-2019-0048_fig_006}

We presented the case within the Italian Rare Cancer Network (IRCN), and the patient started first-line chemotherapy with Gemcitabine (1000 mg/mq, day 1-8-15, IV every 21 days) after two months from the surgical procedure, followed by an immediate clinical improvement after the first cycle. The CT scan evaluation performed three months later, showed a brilliant partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, \[[@j_med-2019-0048_ref_017]\] namely with an almost complete abdominal response and a significant reduction of several lung lesions. A re-assessment CT scan, performed in May 2018, after 11 cycles of therapy, pointed out a severe lung and soft tissue progression. Thus, the patient started second-line chemotherapy with Olaratumab (15 mg/Kg, day 1-8) and Doxorubicin (75 mg/kg, day 1-8) given intravenously every 21 days. Unfortunately, a fast-worsening disease occurred with an impressive progression in lungs, liver, and soft-tissues, confirmed by a total body CT scan assessed after three cycles. The chemotherapy regimen was switched to a weekly Paclitaxel schedule (80 mg/mq). At last, the patient died after four cycles due to hepatic insufficiency. The flow-chart reports the clinical sequence of the patient.

5. Discussion {#j_med-2019-0048_s_005}
=============

Over the past few years, significant concerns emerged about the standard treatment of AS, mainly due to the advances in the understanding of its aggressive behaviour \[[@j_med-2019-0048_ref_001]\]. AS unusually harbours from the kidney, and it was first described by Prince in 1942 \[[@j_med-2019-0048_ref_018]\], after a clear definition of this heterogeneous group of the tumour was set \[[@j_med-2019-0048_ref_019], [@j_med-2019-0048_ref_020]\]. Numerous overlapping radiological characteristics could be observed in particular with RCC \[[@j_med-2019-0048_ref_014], [@j_med-2019-0048_ref_021], [@j_med-2019-0048_ref_022]\].

Nowadays, we noted a prevalence of incidental diagnosis in the RCC, while the most common clinical presentation of AS includes macroscopic hematuria (81%), flank pain (38%), or a palpable renal mass (31%) \[[@j_med-2019-0048_ref_023]\]. Its typical histopathological features are the presence of aberrant vascular structures with malignant endothelial cells.

Primary renal AS has a poor prognosis with a high mortality rate mainly due to local recurrence and an early hematogenous spread. Metastases are usually found at the time of diagnosis or develop within a couple of months after surgery. Thus, the absence of detectable metastases at the time of operation does not improve the survival rate, with a minimal number of patients surviving more than one year \[[@j_med-2019-0048_ref_008]\].

Several substances such as thorium dioxide (Thorotrast^®^) for cerebral angiography, insecticides, and vinyl chloride were linked to the induction of hepatic AS \[[@j_med-2019-0048_ref_006], [@j_med-2019-0048_ref_024], [@j_med-2019-0048_ref_025], [@j_med-2019-0048_ref_026]\]. Conditions associated with the development of AS were radiotherapy, filariasis, chronic lymphedema of any cause (Stewart-Treves syndrome), and von Recklinghausen's disease, with a recently reported case of AS arising in schwannoma of the kidney \[[@j_med-2019-0048_ref_005], [@j_med-2019-0048_ref_027]\]. Another example was said to origin in a polycystic kidney \[[@j_med-2019-0048_ref_010]\]. However, none of these risk factors has been proven to have a direct causal relationship with renal AS. The role of some genes, such as p53, VEGF, Ras, Myc, and MDM2, have been explored but their interaction in the development of tumoral phenotype is far to be found \[[@j_med-2019-0048_ref_011], [@j_med-2019-0048_ref_028]\].

Even if no stable radiological features exist for renal AS, in case of enhancing hypervascular rim and a non-enhancing centre with fast wash-out of the contrast medium, a differential diagnosis with angiomyolipoma shall be done. After that, an advanced RCC and carcinosarcoma should be ruled out \[[@j_med-2019-0048_ref_014], [@j_med-2019-0048_ref_029]\]. In the latter case the interphase sarcomatous component and carcinomatous one result sharp. In the literature, only one instance of a

Von-Hippel-Lindau negative patient exists, showing the presence of minute clear cell carcinomas between AS and non-tumoral renal parenchyma \[[@j_med-2019-0048_ref_030]\]. To our knowledge, one case of fine-needle aspiration cytology with the application of immune-histochemical analysis was reported in an 83-year-old man, referred to the oncologists for primary chemotherapy \[[@j_med-2019-0048_ref_031]\].

The demonstration of endothelial cell line molecules, like CD31, CD34, and human hematopoietic progenitor cell antigen, was accounted with high specificity and sensitivity \[[@j_med-2019-0048_ref_032]\]. Furthermore, the presence of numerous anastomosing small vessels enveloped by polymorphic tumour cells was probably the consequence of the non-hypoxia induced intratumoral activation with an autonomous, non-dependent by Vascular Endothelial Growth Factor (VEGF) tyrosine kinase receptor activation \[[@j_med-2019-0048_ref_033]\]. Cavernous hemangioma-like, sinusoidal and papillary arrangements might also arise in the tumour \[[@j_med-2019-0048_ref_030]\].

![Clinical flow-chart reporting main uro-oncological proceedings](med-14-443-g007){#j_med-2019-0048_fig_007}

![Clinical flow-chart reporting main uro-oncological proceedings continued](med-14-443-g008){#j_med-2019-0048_fig_008}

![Clinical flow-chart reporting main uro-oncological proceedings continued](med-14-443-g009){#j_med-2019-0048_fig_009}

Regarding the treatment of the soft tissue sarcomas, it always involves radical surgery, as margin negativity is crucial for the cure. The role of chemotherapy and radiotherapy remains controversial, even if the latter has demonstrated to improve local control of the disease \[[@j_med-2019-0048_ref_034]\].

The present is an exceptional primary case of AS of the kidney, which updates the limited literature in this field. Beyond its rarity, the lack of information available makes this tumour very difficult to treat. This case occurred in the left kidney of a 56-year-old white man, free of genetic syndromes. He underwent cerebral angiography with thorium dioxide for a cerebrovascular study about thirty years before AS occurrence.

The disease developed insidiously, starting with flank pain, gross hematuria one week before surgery, and weight loss (10 kg in 15 days). Its clinical presentation is in line with that expected by previous reports. Metastases were not detectable at the preoperative CT scan, even if one was suspected in ipsilateral adrenal gland together with infiltration of the psoas muscle. These acquisitions did not stop us from performing a primary surgical strategy to remove all the pathologic tissue since it was demonstrated to be the most effective treatment approach \[[@j_med-2019-0048_ref_035]\]. Based on the histopathological analysis, we found the presence of a benign adenoma, without the involvement of the adrenal gland and the absence of infiltration of the psoas muscle.

The endothelial nature of the neoplastic cells in our case was verified by diffuse positive immune-histochemical staining for the highly sensitive vascular marker CD-34 in 100% of the tumour cells \[[@j_med-2019-0048_ref_009], [@j_med-2019-0048_ref_035]\]. The raising proliferative nature of the tumour is suggested by the Ki-67 index reported to be 30% \[[@j_med-2019-0048_ref_036]\], 40% (9) \[[@j_med-2019-0048_ref_037]\], and \>80% \[[@j_med-2019-0048_ref_038]\] respectively. In our specimen, the Ki-67 index was about 50%, and we now confirm it to indicate a high aggressiveness of this tumour.

After the patient was referred to the oncologist, he performed a two months follow-up CT scan showing local recurrence in the kidney lodge measuring 3 cm and peritoneal, liver, and lung metastases. Although the first line chemotherapy regimen of choice for metastatic AS included anthracyclines plus ifosfamide, often it can be difficult to administer for a suboptimal performance status (PS ECOG 3-4) or advanced age \[[@j_med-2019-0048_ref_017]\].

In this case, the fast-worsening clinical presentation induced to use gemcitabine as the first line, following a retrospective experience collected by the IRCN \[[@j_med-2019-0048_ref_039]\]. As above mentioned, the patient presented an excellent response to the treatment with good progression-free survival of 12 months, but the following line of therapy did not determine any effect, encountering a chemo-refractory disease with a cancer-specific survival of 15 months.

6. Conclusion {#j_med-2019-0048_s_006}
=============

Primary AS of the kidney represents a rare variant of renal parenchymal cancer with a high potential of malignancy, profoundly affecting cancer-specific survival. Our findings add new information about the biology and progression of these neoplasms in the attempt to achieve the definition of a standard approach to this tumour.
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